Anne-Sophie Gautron

Title: Anne-Sophie Gautron: Innovator in Cancer Therapy

Introduction

Anne-Sophie Gautron is a prominent inventor based in Etréchy, France. She has made significant contributions to the field of cancer therapy through her innovative work on chimeric antigen receptors. Her research focuses on developing engineered immune cells that can effectively target and treat specific types of cancers.

Latest Patents

Anne-Sophie Gautron holds a patent for "Universal chimeric antigen receptor T cells specific for CD22." This invention relates to new CD22 Chimeric Antigen Receptors (CD22 CAR), which are engineered immune cells designed to treat relapsed refractory CD22 expressing cancers. The patent highlights the use of these CARs in therapy, showcasing their potential to improve treatment outcomes for patients.

Career Highlights

Gautron is associated with Cellectis S.A., a company known for its pioneering work in gene editing and immunotherapy. Her role at Cellectis has allowed her to collaborate with leading experts in the field, further advancing the development of innovative cancer therapies.

Collaborations

Some of her notable coworkers include Cecile Schiffer-Mannioui and Philippe Duchateau. Their collective expertise contributes to the ongoing research and development efforts at Cellectis.

Conclusion

Anne-Sophie Gautron's work exemplifies the impact of innovation in the medical field, particularly in cancer treatment. Her contributions through patents and collaboration with esteemed colleagues position her as a key figure in advancing therapeutic strategies for challenging cancers.